Navigation Links
Takeda Submits New Drug Application in the U.S. for Azilsartan Medoxomil Plus Chlorthalidone, an Investigational Fixed-Dose Combination for the Treatment of Hypertension
Date:2/23/2011

DEERFIELD, Ill. and OSAKA, Japan, February 23, 2011 /PRNewswire/ -- Takeda Pharmaceutical Company Limited (Takeda) announced today that Takeda Global Research & Development Center, Inc. U.S., submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for an investigational fixed-dose combination of azilsartan medoxomil plus chlorthalidone (CLD) for the treatment of hypertension, or high blood pressure. Discovered by Takeda, azilsartan medoxomil is an angiotensin II receptor blocker (ARB) that lowers blood pressure by blocking the action of angiotensin II, a vasopressor hormone. Chlorthalidone is a long-acting oral thiazide-like diuretic used in the treatment of hypertension. The NDA submission was supported by four phase 3 clinical trials involving more than 4,000 patients with hypertension.

“Millions of patients with hypertension do not have their condition under control,” said Darryl Sleep, M.D., vice president, clinical science, Takeda Global Research & Development Center, Inc. U.S. “We believe this compound, the first in the U.S. to combine an ARB with chlorthalidone, could potentially provide an important new treatment option for patients with hypertension and the health care providers who manage them.”

In a phase 3 clinical trial, azilsartan medoxomil (20 mg/day, 40 mg/day and 80 mg/day), combined in a fixed-dose with CLD (12.5 mg/day and 25 mg/day), was studied versus azilsartan medoxomil and CLD monotherapies. In other studies, the fixed-dose combination of azilsartan medoxomil plus CLD was compared to azilsartan medoxomil coadministered with hydrochlorothiazide (HCTZ), another diuretic, and with a fixed-dose combination of olmesartan medoxomil and HCTZ.

Results from a phase 3 clinical trial of the fixed-dose combination of azilsartan medoxomil plus CLD were previously presented at the American Society of Hypertension, Inc. (ASH), 25th Annual Scientific Meeting and Expositio
'/>"/>

SOURCE Takeda Global Research & Development Center, Inc., U.S.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Takeda Enters Into Global Strategic Partnerships With Covance and Quintiles
2. Takeda Completes Settlements With All Defendants in U.S. Patent Litigation Involving ACTOS® (pioglitazone HCI), ACTOplus met® (pioglitazone HCl and metformin HCl) and duetact® (pioglitazone HCl and glimepiride)
3. Takeda Responds to Announcement about Suspension of Rosiglitazone Marketing Authorization in Europe and Restrictions in the U.S.
4. Arthritis Foundation and Takeda Launch First-Ever National Gout Public Service Announcement (PSA) Campaign, Urging People Living With Gout to Keep Enjoying Lifes Simple Pleasures
5. Orexigen® Therapeutics and Takeda Enter Into Partnership to Commercialize Contrave® in North America
6. Takeda Responds to FDA Advisory Committee Recommendation
7. Takeda Provides Update on Patent Litigation for ACTOS(R) (pioglitazone HCl) and ACTOplus met(R) (pioglitazone HCl and metformin HCl) in the U.S.
8. CellCentric Licenses Novel Epigenetic Discovery Programme to Takeda
9. Amylin and Takeda Announce Decision to Advance Development of Pramlintide/Metreleptin Combination Treatment for Obesity
10. Takeda Announces Initiation of Trial to Study the Concomitant Use of Dexlansoprazole and Other Proton Pump Inhibitors with Plavix(R) (clopidogrel bisulfate)
11. Emerging Agents from Theravance/Astellas, Johnson & Johnson/Basilea and Forest/Astrazeneca/Takeda Will Drive Modest Growth in the MRSA Drug Market Through 2018
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... McGraw-Hill Education Professional, a leading global provider ... medical communities, has announced the launch of the ... the world-renowned medical education platform. A ... available for download onto all iOS and Android devices, ... access to valuable AccessMedicine diagnostic resources in ...
(Date:7/29/2014)... -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced ... 2014 financial results after the Nasdaq market closes on ... live conference call and webcast to discuss its financial ... 7, 2014 at 8:00 a.m. Eastern Time (5:00 a.m. ... conference call by dialing 866-952-1907 (US) or 785-424-1826 (International) ...
(Date:7/29/2014)... July 29, 2014 Research and Markets ... Respiratory Devices Market 2014-2018" report to their offering. ... A respiratory device is a medical device used to ... difficulty in breathing and cannot achieve adequate oxygen levels ... cystic fibrosis, asthma, COPD, and ARDS require the need ...
Breaking Medicine Technology:McGraw-Hill Education Professional's AccessMedicine App Delivers Instant Access to Essential Diagnostic Tools 2McGraw-Hill Education Professional's AccessMedicine App Delivers Instant Access to Essential Diagnostic Tools 3Neurocrine Biosciences Announces Conference Call And Webcast To Report Second Quarter 2014 Financial Results 2Global Respiratory Devices Market 2014-2018 2
(Date:7/29/2014)... Hopkins researchers say they have discovered a chemical alteration ... that, if confirmed in larger studies, could give doctors ... risk of attempting suicide. , The discovery, described online ... that changes in a gene involved in the function ... significant role in turning what might otherwise be an ...
(Date:7/29/2014)... Diabetes is a common condition diagnosed in millions of people. ... while the production of insulin is decreased. , Insulin ... needed by the body to regulate blood sugar levels. Diabetes ... as there are numerous complications that can be developed by ... read a complex review of Matt Traverso's new book go ...
(Date:7/29/2014)... For numerous women from all over the world, ... out being quite hard. Well, the author of the Make ... that can help all these women. This is the formula ... love and attention every day. , Daily Gossip reveals ... by Alex Carter who published a unique eBook to detail ...
(Date:7/29/2014)... Daily Gossip writes in its Fibroids Miracle review that this ... users how to permanently eliminate uterine fibroids. The system has ... the world. , They have been able to get ... as 12 hours. This means that pain and other disturbing ... Fibroids Miracle review also indicates that the method was developed ...
(Date:7/29/2014)... July 29, 2014 (HealthDay News) -- Want young children ... them something that,s healthy is good for them. Doing ... good, a new study suggests. "Parents and caregivers ... may be better off simply serving the food without ... yummy the food actually is," said study authors Michal ...
Breaking Medicine News(10 mins):Health News:A blood test for suicide? 2Health News:A blood test for suicide? 3Health News:Reverse Your Diabetes Today Review Exposes Matt Traverso’s New eBook 2Health News:"Make Him Desire You" Review Reveals Unique Formula to Make Men Feel a Special Kind of Love 2Health News:Amanda Leto’s Fibroids Miracle Review Reveals Clinically Proven Uterine Fibroids Cure System 2Health News:Kids Will Pass on 'Healthy' Foods 2
... The Substance Abuse and,Mental Health Services Administration ... inaugural Science and Service Awards. These awards,recognize ... treat mental illnesses and substance abuse., ... to public sector,organizations and community-based groups and ...
... Collection Donates 100% of Net Profits to The ... Ovarian Cancer Research Fund, ... anniversary of its partnership with The Ovarian Cancer Research,Fund (OCRF) and ... decade, L,Oreal Paris has offered hope to the tens of,thousands of ...
... Sicko Serve as Reminder of Need for Genuine Reform -,Nurses ... ... International Nurses Panel Lauds Guaranteed Healthcare Systems, ... Michael Moore,s Sicko will lead a delegation of several,hundred registered ...
... the pharmacys name or logo rather than instructions on ... in the September 10 issue of the Archives of ... 1.5 million medication errors occur each year in the ... the mistakes. While the Food and Drug Administration has ...
... medications again, study finds , , TUESDAY, Sept. 11 (HealthDay ... chronic health problems such as high blood pressure and ... prescription drug plans, new research shows. , The ... also found that many of those seniors do not ...
... The Innovative Vector Control Consortium (IVCC) has embarked ... year strategy with the launch of the first ... health mosquito control products. The three projects, ... IVCC projects developing improved mosquito control information systems. ...
Cached Medicine News:Health News:SAMHSA Announces First Science and Service Award Winners 2Health News:SAMHSA Announces First Science and Service Award Winners 3Health News:SAMHSA Announces First Science and Service Award Winners 4Health News:L'Oreal Paris Celebrates Ten Years of Hope and Healing 2Health News:L'Oreal Paris Celebrates Ten Years of Hope and Healing 3Health News:L'Oreal Paris Celebrates Ten Years of Hope and Healing 4Health News:L'Oreal Paris Celebrates Ten Years of Hope and Healing 5Health News:September 11th First Responders Lead Emotional Rally at State Capitol Tuesday 2Health News:Prescription labels geared toward pharmacies, not patients 2Health News:Medicare Spending Caps Cause Seniors to Stop Meds 2Health News:IVCC launches groundbreaking insecticide projects with Bayer and Syngenta 2
... dedicated fluorometer from Berthold Technologies, has ... variety of measurement modes to support ... scanning, dual ratio measurements plus top ... valuable instrument for any researcher using ...
The VICTOR² D fluorometer is suitable for clinical assays based on fluorescence or time-resolved fluorescence from a wide variety of plates....
... VISUCAM non-mydriatic fundus camera ... simplicity of fundus imaging. ... to set the standard ... features a unique combination ...
Small, compact and versatile, the CLK-4 light source is compatible with all Olympus fiberscopes and is ideal for the vast majority of routine fiber-endoscopic procedures, especially in the out-patien...
Medicine Products: